Phase I and pharmacokinetic trial of weekly oral fluorouracil given with eniluracil and low-dose leucovorin to patients with solid tumors

Journal of Clinical Oncology

Volumn 18, Issue 23, 2000, Pages 3952-3963

  Grem, Jean L ^a   Harold, Nancy ^a   Shapiro, Jeremy ^a   Bi, Dao Qin ^a   Quinn, Mary G ^a   Zentko, Suzanne ^a   Keith, Bruce ^a   Hamilton, J Michael ^a   Monahan, Brian P ^a   Donavan, Sean ^a   Grollman, Frank ^a   Morrison, Geraldine ^a   Takimoto, Chris H ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 ETHYNYLURACIL; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; FOLINIC ACID;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG CLEARANCE; DRUG TOLERANCE; ENZYME INACTIVATION; FATIGUE; FEMALE; HUMAN; MALE; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR;

EID: 0034551725     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.23.3952     Document Type: Article

References (49)

1. 5-Fluorinated pyrimidines
2. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: A Mid-Atlantic Oncology Program study
3. Phase II study of fluorouracil and its modulation in advanced colorectal cancer: A Southwest Oncology Group study
4. Phase III study of bolus versus infusion fluorouracil with or without cisplatin in advanced colorectal cancer
5. 5-Fluorouracil (5-FU) continuous intravenous infusion compared with bolus administration: Final results of a randomised trial in metastatic colorectal cancer
6. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer
7. A randomized phase I and phase II study of short-term infusion of high-dose fluorouracil with or without N-(phosphonacetyl)-L-aspartic acid in patients with advanced pancreatic and colorectal cancers
8. High-dose 24-hour infusion of 5-fluorouracil in metastatic prostate cancer: A phase II trial of the Piedmont Oncology Association
9. Phase I trial of 5-fluorouracil by 24-hour infusion weekly
10. Weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin in the treatment of advanced gastric cancers: An effective and low-toxic regimen for patients with poor general condition
11. Phase III trial of biochemical modulation of 5-fluorouracil by IV or oral leucovorin or by interferon in advanced colorectal cancer: An ECOG/CALGB phase III trial
12. Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: Results of a randomized trial in patients with advanced colorectal cancer
13. Mechanism-based inactivation of dihydropyrimidine dehydrogenase by 5-ethynyluracil
14. 5-Ethynyluracil (776C85): A potent modulator of the pharmacokinetics and antitumor efficacy of 5-fluorouracil
15. 5-Ethynyluracil (776C85): Inactivation of dihydropyrimidine dehydrogenase in vivo
16. Dihydropyrimidine dehydrogenase inactivation and 5-fluorouracil pharmacokinetics: Allometric scaling of animal data, pharmacokinetics and toxicodynamics of 5-fluorouracil in humans
17. Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase
18. Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer
19. Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancer
20. Pharmacokinetics and tissue distribution of 2-fluoro-beta-alanine in rats: Potential relevance to toxicity pattern of 5-fluorouracil
21. Experimental neurotoxicity of 5-fluorouracil and its derivatives is due to poisoning by the monofluorinated organic metabolites, monofluoroacetic acid and alpha-fluoro-beta-alanine
22. Metabolites of 5-fluorouracil, alpha-fluoro-beta-alanine and fluoroacetic acid, directly injure myelinated fibers in tissue culture
23. Attenuation of the antitumor activity of 5-fluorouracil by (R)-5-fluoro-5,6-dihydrouracil
24. 5-Ethynyluracil (776C85): Protection from 5-fluorouracil-induced neurotoxicity in dogs
25. Dihydropyrimidine dehydrogenase activity and messenger RNA level may be related to the antitumor effect of 5-fluorouracil on human tumor xenografts in nude mice
26. Dihydropyrimidine dehydrogenase: A tumoral target for fluorouracil modulation
27. Response to fluorouracil therapy in cancer patients: The role of tumoral dihydropyrimidine dehydrogenase activity
28. Quantitation of dihydropyrimidine dehydrogenase expression in tumor specimens of patients treated with 5-fluorouracil using a quantitative polymerase chain reaction assay
29. Eniluracil treatment completely inactivates dihydropyrimidine dehydrogenase in colorectal tumors
30. Gas chromatographic-mass spectrometric method for routine monitoring of 5-fluorouracil in plasma of patients receiving low-level protracted infusions
31. Measurement of plasma uracil using gas chromatography-mass spectrometry in normal individuals and in patients receiving inhibitors of dihydropyrimidine dehydrogenase
32. Simultaneous gas chromatographic-mass spectrophotometric determination of alpha-fluoro-beta-alanine and 5-fluorouracil in plasma
33. Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: Population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy
34. Decreased dihydropyrimidine dehydrogenase activity in a population of patients with breast cancer: Implication for 5-fluorouracil-based chemotherapy
35. Phase I and pharmacologic study of oral fluorouracil on a chronic daily schedule in combination with the dihydropyrimidine dehydrogenase inactivator eniluracil
36. 2 x 2 daily) as first-line chemotherapy in patients with advanced breast cancer: A phase II study
37. A phase II open-label study to evaluate a 28-day regimen of oral 5-fluorouracil plus 776C85 for the treatment of patients with previously untreated metastatic colorectal cancer
38. Dihydropyrimidine dehydrogenase activity in cancer patients
39. Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity
40. Lethal drug interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs
41. The effect of sorivudine on dihydropyrimidine dehydrogenase activity in patients with acute herpes zoster
42. Preclinical and phase I clinical studies with the nonclassical antifolate thymidylate synthase inhibitor nolatrexed dihydrochloride given by prolonged administration in patients with solid tumors
43. Phase I trial of the thymidylate synthase inhibitor AG331 as a 5-day continuous infusion
44. Interaction of deoxyuridine with fluorouracil and dipyridamole in a human colon cancer cell line
45. Immunoreactive dUMP and TTP pools as an index of thymidylate synthase inhibition: Effect of tomudex (ZD1694) and a nonpolyglutamated quinazoline antifolate (CB30900) in L1210 mouse leukaemia cells
46. Modulation of fluorouracil cytotoxicity by interferons alpha and gamma
47. 19F nuclear magnetic resonance spectroscopy
48. Characterization of dihydropyrimidine dehydrogenase in human colorectal tumours
49. 5-Ethynyluracil (776C85): Modulation of 5-fluorouracil efficacy and therapeutic index in rats bearing advanced colorectal carcinoma